3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
2
Completed
2
Terminated
1
Enrolling by invitation
1
Available
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Waldenstrom Macroglobulinemia
1
Recurrence
1
Leukemia, Hairy Cell
1
Burkitt Lymphoma
1
Interventions
pembrolizumab
33
Carboplatin
18
Cisplatin
15
Nivolumab
14
Pemetrexed
12
Paclitaxel
12
Ipilimumab
11
atezolizumab
10
Gemcitabine
10
venetoclax
9
Radiotherapy
9
Docetaxel
9
durvalumab
8
Cyclophosphamide
8
fludarabine
7
Specimen Handling
7
Biopsy
7
Bevacizumab
7
tislelizumab
6
enzalutamide
6
Trastuzumab
6
Practice Guidelines as Topic
6
Cetuximab
6
tazemetostat
5
fludarabine phosphate
5
Surveys and Questionnaires
5
Standard of Care
5
Radiosurgery
5
Magnetic Resonance Spectroscopy
5
Injections
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
brexucabtagene autoleucel
×
90 days
×
Clear all
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts